Skip to main content
. 2023 Oct 16;35(2):e14. doi: 10.3802/jgo.2024.35.e14

Table 2. Patient demographics and tumor characteristics (n=208).

Characteristics VPD L-VPD p-value
Patients, n/tot, (%) 158 (76.0) 50 (24.0) <0.05
Age (yr) 68 (54–78) 62 (51–74) 0.7
Histology 0.7
HGSOC 130 (82.3) 40 (80.0)
Non HGSOC 28 (17.7) 10 (20.0)
FIGO stage 0.6
IIIC 120 (75.9) 44 (88.0)
IV 38 (24.1) 6 (12.0)
u-VPD 71 (44.9) 16 (32.0) 0.1
i-VPD 87 (55.1) 34 (68.0)
CA-125 U/mL at diagnosis 819 (129–3,670) 645 (112–1,187) <0.05
CA-125 U/mL at i-VPD 190 (15–615) 90 (5–250) <0.005
ECOG 0–1 48 (30.4) 31 (62.0) <0.005
ECOG 2 110 (69.6) 19 (38.0)

Values are presented as number (%) or mean (range).

CA-125, cancer antigen 125; ECOG, Eastern Cooperative Oncology Group Performance Status Scale; FIGO, International Federation of Gynecology and Obstetrics; HGSOC, high grade serous ovarian cancer; i-VPD, interval visceral-peritoneal debulking; L-VPD, laparoscopic visceral-peritoneal debulking; u-VPD, upfront visceral-peritoneal debulking; VPD, visceral-peritoneal debulking.